KalVista Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for KalVista Pharmaceuticals, Inc. (KALV) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019
Operating Activities
Net Income-183.44-126.64-92.91-82.34-46.24-29.12-20.82
Depreciation & Amortization0.940.890.723.171.190.710.38
Stock Based Compensation0.0021.929.9211.097.120.000.00
Change in Working Capital15.046.997.41-7.120.89-14.86-18.79
Change in Accounts Receivable-3.620.000.000.000.000.000.00
Change in Accounts Payable-4.974.321.111.690.150.000.00
Change in Other Working Capital23.63-0.016.31-14.018.200.000.00
Other Operating Activities14.5630.08-1.536.0614.69-1.320.00
Net Cash from Operating Activities-152.91-89.23-75.26-78.13-30.17-44.82-36.37
Investing Activities
Capital Expenditures-0.430.44-1.200.930.080.22-1.08
Purchases of Investments-30.57-189.2342.6158.79-147.570.000.00
Sales/Maturities of Investments122.52-84.2842.6158.79-147.5716.97-68.34
Net Cash from Investing Activities91.02-84.7241.4257.86-147.6516.75-69.42
Financing Activities
Debt Repayment98.040.000.000.000.00-0.05-0.21
Common Stock Issued61.6997.5957.031.58212.1211.6487.91
Other Financing Activities0.0053.121.090.000.000.000.00
Net Cash from Financing Activities159.73150.7158.121.58212.1211.5887.94
Summary
Effect of Forex Changes on Cash1.98-1.211.24-1.170.510.26-1.21
Net Change in Cash99.83-23.2425.51-18.6934.80-16.22-17.84
Cash at Beginning of Period31.7956.2430.7350.5915.7932.0151.06
Cash at End of Period131.6231.7956.2430.7350.5915.7932.01
Free Cash Flow-153.34-89.27-76.46-79.07-30.25-45.04-37.45